↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Readers on

mendeley
373 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Published in
Lancet Oncology, January 2018
DOI 10.1016/s1470-2045(18)30006-8
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 373 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 373 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 44 12%
Student > Ph. D. Student 38 10%
Student > Bachelor 32 9%
Student > Master 31 8%
Other 27 7%
Other 62 17%
Unknown 139 37%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 121 32%
Biochemistry, Genetics and Molecular Biology 29 8%
Agricultural and Biological Sciences 15 4%
Nursing and Health Professions 12 3%
Immunology and Microbiology 12 3%
Other 33 9%
Unknown 151 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 43. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2026.
All research outputs
#1,226,806
of 34,411,289 outputs
Outputs from Lancet Oncology
#1,547
of 7,984 outputs
Outputs of similar age
#21,825
of 495,536 outputs
Outputs of similar age from Lancet Oncology
#33
of 132 outputs
Altmetric has tracked 34,411,289 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,984 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 495,536 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.